Karyopharm delays third-quarter report amid bankruptcy proceedings
KPTI•Karyopharm Therapeutics said it cannot file its third-quarter report by the deadline or within the five-day extension, and has not estimated a filing date. Its proposed reorganization plan would cancel existing equity without distributions; the Ayrmid merger is expected to close in the first quarter of 2027.
1. Filing delay
Karyopharm Therapeutics said Chapter 11 proceedings begun November 2, 2026, diverted management resources, while limited finance and accounting staffing also contributed to its inability to file a quarterly report for the period ended September 30 by the deadline or within the permitted five-day extension. Closing procedures and technical accounting assessments remain incomplete, and the company has not estimated a filing date.
2. Expected results and plan
The company expects results for the three and nine months to differ significantly from 2025, primarily reflecting bankruptcy preparation and strategic transaction costs. Its proposed reorganization plan would cancel existing equity without distributions, and the Ayrmid merger is expected to close in the first quarter of 2027.
